Dynavax Technologies (NASDAQ: DVAX) has been chock-full of good news so far this year. Earlier this month, the company announced plans to initiate a phase 2/3 clinical study of Clover Biopharmaceuticals' COVID-19 vaccine candidate with Dynavax's CpG 1018 adjuvant. The U.K. ordered an extra 40 million doses of another COVID vaccine that uses the company's adjuvant. And Dynavax won a $99 million deal with the Coalition for Epidemic Preparedness Innovations (CEPI) to supply CpG 1018.
You can now add even more good news to the list. Dynavax announced its fourth-quarter results after the market closed on Thursday. Here are the highlights from the company's Q4 update.
Image source: Getty Images.
For further details see:
Dynavax's Q4 Results Show It's Not Just About Heplisav-B Anymore